NWBO refutes false rumors of MHRA rejection; MHRA confirms DCVax-L MAA still under review

NORTHWEST BIOTHERAPEUTICS INC

MHRA confirmed DCVax-L MAA for glioblastoma remains under initial review, not refused, withdrawn, or appealed.
Company categorically refutes false rumors of MHRA rejection and notes possible stock manipulation.
Rumors intensified after BNOS Annual Meeting where significant Phase 3 trial data were presented.
Company continues constructive interactions with MHRA; MAA progressing towards first regulatory decision.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.